Evaluation of ICP-B208 in Patients With Advanced Solid Tumors

Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Study ID
NCT07617493
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • ICP-B208 — DRUG
    ICP-B208 will be administered by intravenous infusion every 3 weeks (Q3W) until disease progression (PD) or the occurrence of unacceptable toxicity or withdrawal from the study for other reasons (whichever occurs first).

Study Details

To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B208 in the trial participants of unresectable advanced or metastatic solid tumors

Key Dates

First listed
Jun 1, 2026
Start date
Jul 3, 2026
Status verified
Jul 2026
Primary completion
Dec 31, 2030
Completion
Jun 30, 2031

Study Design

Enrollment
539 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: ICP-B208

Primary Outcome Measure

The types, severity, correlation with the investigational drug and incidence of adverse events and serious adverse events [ Time Frame: 2 years ]

Central Contacts

Related Studies